Pharmacologic ascorbate resistant pancreatic cancer demonstrates enhanced metastatic potential.

ABSTRACT: Pharmacological ascorbate (P-AscH, high-dose, intravenous, vitamin C), is a pro-drug that generates hydrogen peroxide (H₂O₂) and is being investigated as a neoadjuvant treatment for pancreatic adenocarcinoma (PDAC). In a randomized, phase II clinical trial, P-AscH demonstrated encouraging results in terms of efficacy and safety. However, some patients do not respond to P-AscH suggesting that resistance occurs in a subset of patients. The aims of this study were two-fold: first to characterize PDAC cells resistant to P-AscH, and second, determine if these alterations enhance metastatic potential. Resistance to P-AscH increased the ability to detoxify H₂O₂, altered redox metabolism and cell cycle regulation, however mechanisms to P-AscH resistance

SUBMITTER: Pope A 

PROVIDER: S-EPMC12158610 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature